332 related articles for article (PubMed ID: 25811877)
1. Functional genomic analysis identifies indoxyl sulfate as a major, poorly dialyzable uremic toxin in end-stage renal disease.
Jhawar S; Singh P; Torres D; Ramirez-Valle F; Kassem H; Banerjee T; Dolgalev I; Heguy A; Zavadil J; Lowenstein J
PLoS One; 2015; 10(3):e0118703. PubMed ID: 25811877
[TBL] [Abstract][Full Text] [Related]
2. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.
Niwa T; Takeda N; Tatematsu A; Maeda K
Clin Chem; 1988 Nov; 34(11):2264-7. PubMed ID: 3141084
[TBL] [Abstract][Full Text] [Related]
4. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.
Deguchi T; Ohtsuki S; Otagiri M; Takanaga H; Asaba H; Mori S; Terasaki T
Kidney Int; 2002 May; 61(5):1760-8. PubMed ID: 11967025
[TBL] [Abstract][Full Text] [Related]
5. Increasing the removal of protein-bound uremic toxins by liposome-supported hemodialysis.
Shi Y; Wang Y; Ma S; Liu T; Tian H; Zhu Q; Wang W; Li Y; Ding F
Artif Organs; 2019 May; 43(5):490-503. PubMed ID: 30375673
[TBL] [Abstract][Full Text] [Related]
6. [The uremic toxin, indoxyl sulfate, signifies cardio-renal risk and intestinal-renal relationship].
Kiss I
Orv Hetil; 2011 Oct; 152(43):1724-30. PubMed ID: 21983398
[TBL] [Abstract][Full Text] [Related]
7. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
[TBL] [Abstract][Full Text] [Related]
8. Differences in Dialysis Efficacy Have Limited Effects on Protein-Bound Uremic Toxins Plasma Levels over Time.
Krieter DH; Kerwagen S; Rüth M; Lemke HD; Wanner C
Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30654454
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
Yamamoto S
Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
[TBL] [Abstract][Full Text] [Related]
10. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease.
Nazzal L; Roberts J; Singh P; Jhawar S; Matalon A; Gao Z; Holzman R; Liebes L; Blaser MJ; Lowenstein J
Nephrol Dial Transplant; 2017 Nov; 32(11):1809-1817. PubMed ID: 28379433
[TBL] [Abstract][Full Text] [Related]
11. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.
Zhang ZH; Mao JR; Chen H; Su W; Zhang Y; Zhang L; Chen DQ; Zhao YY; Vaziri ND
Clin Biochem; 2017 Dec; 50(18):1078-1086. PubMed ID: 28928007
[TBL] [Abstract][Full Text] [Related]
12. Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial.
Sirich TL; Fong K; Larive B; Beck GJ; Chertow GM; Levin NW; Kliger AS; Plummer NS; Meyer TW;
Kidney Int; 2017 May; 91(5):1186-1192. PubMed ID: 28089366
[TBL] [Abstract][Full Text] [Related]
13. Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients.
Paats J; Adoberg A; Arund J; Dhondt A; Fernström A; Fridolin I; Glorieux G; Leis L; Luman M; Gonzalez-Parra E; Perez-Gomez VM; Pilt K; Sanchez-Ospina D; Segelmark M; Uhlin F; Arduan Ortiz A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102247
[TBL] [Abstract][Full Text] [Related]
14. High-volume hemodiafiltration decreases the pre-dialysis concentrations of indoxyl sulfate and p-cresyl sulfate compared to hemodialysis: a post-hoc analysis from the HDFit randomized controlled trial.
Lima JD; Guedes M; Rodrigues SD; Flórido ACS; Moreno-Amaral AN; Barra AB; Canziani ME; Cuvello-Neto A; Poli-de-Figueiredo CE; Pecoits-Filho R; Nakao LS
J Nephrol; 2022 Jun; 35(5):1449-1456. PubMed ID: 35239175
[TBL] [Abstract][Full Text] [Related]
15. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells.
Motojima M; Hosokawa A; Yamato H; Muraki T; Yoshioka T
Kidney Int; 2003 May; 63(5):1671-80. PubMed ID: 12675842
[TBL] [Abstract][Full Text] [Related]
16. Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.
Kalim S; Wald R; Yan AT; Goldstein MB; Kiaii M; Xu D; Berg AH; Clish C; Thadhani R; Rhee EP; Perl J
Clin J Am Soc Nephrol; 2018 Mar; 13(3):436-444. PubMed ID: 29444900
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Indoxyl-beta-D-glucuronide and 3-indoxyl sulfate in plasma of hemodialysis patients.
Agatsuma S; Sekino H; Watanabe H
Clin Nephrol; 1996 Apr; 45(4):250-6. PubMed ID: 8861801
[TBL] [Abstract][Full Text] [Related]
19. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor.
Chitalia VC; Shivanna S; Martorell J; Balcells M; Bosch I; Kolandaivelu K; Edelman ER
Circulation; 2013 Jan; 127(3):365-76. PubMed ID: 23269489
[TBL] [Abstract][Full Text] [Related]
20. HPLC study of uremic fluids related to optical dialysis adequacy monitoring.
Lauri K; Tanner R; Jerotskaja J; Luman M; Fridolin I
Int J Artif Organs; 2010 Feb; 33(2):96-104. PubMed ID: 20306436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
